Thursday, September 1, 2011
Keryx Biopharmaceuticals Inc., of New York, said the independent data safety monitoring board for the firm's pivotal Phase III X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) study of perifosine (KRX-0401) in refractory advanced colorectal cancer completed a pre-specified interim safety and futility analysis and recommended the trial continue as planned. The study has completed enrollment, with more than 465 patients, and is being conducted under a special protocol assessment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.